Overview
- U.S. Bankruptcy Judge Brian C. Walsh approved the sale of substantially all 23andMe assets to TTAM Research Institute for $305 million.
- Under the agreement, TTAM will acquire 23andMe’s Personal Genome Service, research services and its Lemonaid Health telemedicine subsidiary.
- The transaction is expected to close in the coming weeks, after which customers will receive emails detailing TTAM’s commitment to uphold existing privacy policies with options to delete data or opt out of research.
- The sale replaces a $256 million bid by Regeneron Pharmaceuticals, ending a competitive auction launched after 23andMe’s March bankruptcy filing.
- California, Kentucky, Tennessee, Texas and Utah remain actively opposed to the sale, citing unresolved concerns under state genetic privacy laws.